An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy [Studio di fase II sull'uso di panobinostat associato a bortezomib e desametasone come terapia di induzione in pazienti con mieloma multiplo candidati ad una terapia ad alte dosi]

Trial Profile

An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy [Studio di fase II sull'uso di panobinostat associato a bortezomib e desametasone come terapia di induzione in pazienti con mieloma multiplo candidati ad una terapia ad alte dosi]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 23 May 2013 Status changed from suspended to discontinued as reported by European Clinical Trials Database.
    • 02 Mar 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
    • 04 Jan 2013 Planned End Date (15 Oct 2018) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top